Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipocine Inc LPCN

Healthcare Biotechnology
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor... see more

Recent & Breaking News (NDAQ:LPCN)

Lipocine to Present at 15th Annual Needham & Company Healthcare Conference

GlobeNewswire April 6, 2016

Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at ENDO 2016

GlobeNewswire March 28, 2016

Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at the American Society of Andrology 41st Annual Conference

GlobeNewswire March 28, 2016

Lipocine Announces Financial and Operational Results for the Full Year of 2015

GlobeNewswire March 10, 2016

Lipocine to Present at 28th Annual Roth Conference

GlobeNewswire March 8, 2016

Past Winner Spotlight: ENDV, PPCH, EYES, LPCN, GALE

Accesswire February 29, 2016

Lipocine Reports Positive Results of LPCN 1107 Study for the Prevention of Preterm Birth

Press Releases February 16, 2016

Lipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women

Press Releases February 16, 2016

Lipocine Announces First Patient Dosed in Phase 2B Clinical Study for LPCN 1111, a Novel Testosterone Replacement Therapy

GlobeNewswire January 4, 2016

Market Influences That Drive Equities Forward - New Research on Lipocine, Imprivata, Ardelyx and Vital Therapies

Accesswire December 15, 2015

Lipocine to Present at 27th Annual Piper Jaffray Healthcare Conference

GlobeNewswire November 24, 2015

Analyst Insights behind Price Movement - Research on Lipocine, Syneron Medical, Republic Airways and Accretive Health

Accesswire November 24, 2015

Origins of Technical Movement, Pricing Tomorrow - Research on Lipocine, Syneron Medical, Republic Airways Holdings, and Accretive Health

Accesswire November 16, 2015

Lipocine Adopts Stockholder Rights Plan

GlobeNewswire November 13, 2015

Lipocine Announces Financial and Operational Results for the Third Quarter of 2015

GlobeNewswire November 12, 2015

Lipocine Announces PDUFA Goal Date for LPCN 1021 NDA

GlobeNewswire November 12, 2015

Lipocine Announces Presentation of LPCN 1021 Clinical Data at 21st Annual SMSNA Meeting

GlobeNewswire November 11, 2015

FDA Accepts for Filing Lipocine's New Drug Application for Its Oral Testosterone Replacement Product Candidate, LPCN 1021

GlobeNewswire October 29, 2015

Lipocine Announces First Subject Dosed in Multi-Dose PK Study for Its Oral Product Candidate for the Prevention of Pre-Term Birth

GlobeNewswire September 28, 2015

Lipocine to Present at Ladenburg Thalmann 2015 Healthcare Conference

GlobeNewswire September 22, 2015